ClinicalTrials.gg
CompletedNCT01223131Lantus-P-CNUpdated Apr 1, 2014

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

A Phase 3 interventional study of Insulin glargine (HOE901) and NPH insulin in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 10 sites in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-04-01.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
23rd of 66
162 · median 73
Started
2011
with 7 others
Phase 3
18 of 66
none open now
Registered
26th of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 23rd largest by enrollment, is one of 8 that started in 2011, is one of 18 in phase 3, and was the 26th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

6 To assess the efficacy of insulin glargine given once daily (QD) on glycosylated hemoglobin (HbA1c) levels over a period of 24 weeks in children with type 1 diabetes mellitus (T1DM) aged at least 6 years to less than 18 years.

Secondary Objectives:

  • To assess the effects of insulin glargine compared to NPH insulin over 24 weeks on:

    • Percentage of patients reaching International Society of Pediatric and Adolescent Diabetes (ISPAD) recommended target of HbA1c \< 7.5%,
    • Fasting blood glucose (FBG),
    • Nocturnal blood glucose (BG),
    • 24-hour blood glucose profile based on 8-point self-monitoring of blood glucose (SMBG) values,
    • Daily total insulin dose and basal insulin dose,
    • Rates of asymptomatic and/or symptomatic, severe, nocturnal and nocturnal symptomatic hypoglycemia.
  • To assess the safety and tolerability of insulin glargine versus NPH insulin based on the occurrence of treatment-emergent adverse events (TEAEs).
  • To assess anti-insulin and anti-glargine antibody development in both groups.
  • To assess insulin glargine pharmacokinetic(PK) for all patients treated with insulin glargine in selected sites with approximately 45% of insulin glargine population to rule out accumulation tendency of insulin glargine after repeated dosing
Read the detailed description

The study duration for each patient is 28 weeks +/- 7 day broken down as follows:

  • Screening phase: up to 2 weeks
  • Run-in phase: 1 week
  • Treatment phase: 24 weeks
  • Follow-up: 1 week
03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Paediatric patients diagnosed with T1DM aged at least 6 years to less than 18 years at screening.

Exclusion criteria

Exclusion criteria:

  • Treatment with oral or parenteral glucose-lowering medications other than insulin.
  • \< 7% or > 12 % at screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Insulin glargine

    injection once daily at bedtime

    Drug: Insulin glargine (HOE901)

  • Active comparator
    NPH insulin

    injection once daily at bedtime or twice daily in the morning and at bedtime

    Drug: NPH insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute change of glycosylated hemoglobin (HbA1c)

    Time frame: from baseline to week 24

Secondary outcomes

  1. Percentage of patients reaching HbA1c < 7.5%

    Time frame: at week 24

  2. Change in Fasting Blood Glucose (FBG)

    Time frame: from baseline to week 24

  3. Change in nocturnal Blood Glucose (BG)

    Time frame: from baseline to week 24

  4. Change in 24-hour blood glucose profile based on 8-point self-monitoring blood glucose (SMBG)

    Time frame: from baseline to week 24

  5. Change in total insulin dose and basal insulin dose

    Time frame: from baseline to week 24

  6. Rate of asymptomatic and/or symptomatic, severe, nocturnal, nocturnal symptomatic hypoglycemia.

    Time frame: during 24-week treatment period

  7. Anti-glargine and anti-human insulin antibody assessment

    Time frame: at screening, week 4, week 24

07

Study locations

10 sites
  • Investigational Site Number 156006
    Beijing, 100020, China
  • Investigational Site Number 156001
    Beijing, 100045, China
  • Investigational Site Number 156007
    Beijing, 100730, China
  • Investigational Site Number 156009
    Changsha, 410011, China
  • Investigational Site Number 156008
    Guangzhou, 510630, China
  • Investigational Site Number 156004
    Hangzhou, 310003, China
  • Investigational Site Number 156016
    Shanghai, 200040, China
  • Investigational Site Number 156005
    Shanghai, 201102, China
  • Investigational Site Number 156019
    Taiyuan, 030013, China
  • Investigational Site Number 156002
    Wuhan, 430030, China
08

References and documents

Publications

  • Liu M, Zhou Z, Yan J, Li P, Song W, Fu J, Chen X, Zhao W, Xi L, Luo X, Sha L, Deng X, Gong C. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus. BMC Endocr Disord. 2016 Nov 26;16(1):67. doi: 10.1186/s12902-016-0146-2. PubMed 27887605 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2010
First posted
Oct 18, 2010
Start
Feb 2011
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Apr 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01223131
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 18, 2010
Start date
Feb 2011
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Apr 1, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion